This research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin
can be safely combined in the treatment of metastatic urothelial carcinoma (mUC).
The names of the study drugs in this investigational combination are:
- Enfortumab Vedotin
- Sacituzumab Govitecan